Do I have this right? Cytodyn's 2012 Equity Incent
Post# of 153771
(Total Views: 888)
Posted On: 09/02/2020 10:22:56 PM
Do I have this right? Cytodyn's 2012 Equity Incentive Plan is currently authorized for 25 million shares, of which, 23,837,489 have already been granted and there's another 9,326,250 that have been awarded pending shareholder approval. So, if the 50 million is approved that will leave a balance of 16,836,261. This is the "Share Reserve", and it will automatically increase on June 1 each year by approximately 6 million shares. So, the ask here is really for another 25 mil now + another 54 million by June 1 2030? I guess they don't like asking every year or two!
Seems like a gutsy ask at this point. Taking a look at the already (pending shareholder approval) awarded shares it appears the lion's share is going to the CEO with 5.5 million of those 9.3 million shares. What's that, almost 60%? Is NP or future CEO going to continue to consume the majority of the shares meant to attract and retain talent? If it continues at this rate under this requested plan that's roughly 40 million shares to be used over the next 10 years to retain a CEO. Seems high to me, even with approval.
And, maybe I'm reading this wrong but it looks to me that CytoDyn management just awarded 5.5 million shares to NP on June 15th? For what? To help cover the 6 million shares forfeited for not reaching a performance goal (cancer BTD). How about holding off on the raises and awards until AFTER leronlimab comes to market?
I'm definitely leaning towards 'NO'. Should I be looking at this differently?
btw - Great news on the call today and I'm very much excited about both near term and long term prospects for CytoDyn.
Seems like a gutsy ask at this point. Taking a look at the already (pending shareholder approval) awarded shares it appears the lion's share is going to the CEO with 5.5 million of those 9.3 million shares. What's that, almost 60%? Is NP or future CEO going to continue to consume the majority of the shares meant to attract and retain talent? If it continues at this rate under this requested plan that's roughly 40 million shares to be used over the next 10 years to retain a CEO. Seems high to me, even with approval.
And, maybe I'm reading this wrong but it looks to me that CytoDyn management just awarded 5.5 million shares to NP on June 15th? For what? To help cover the 6 million shares forfeited for not reaching a performance goal (cancer BTD). How about holding off on the raises and awards until AFTER leronlimab comes to market?
I'm definitely leaning towards 'NO'. Should I be looking at this differently?
btw - Great news on the call today and I'm very much excited about both near term and long term prospects for CytoDyn.
(9)
(0)